US SB2737 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on September 7 2023 - 25% progression, died in committee
Action: 2023-09-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 7 2023 - 25% progression, died in committee
Action: 2023-09-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to require the Food and Drug Administration to determine whether to permit the use of enriched enrollment randomized withdrawal methodology with respect to clinical trials.
Title
FREED of Opioids Act FDA Review of Efficacy of EERW Double-Blinds of Opioids Act
Sponsors
| Sen. Joe Manchin [D-WV] | Sen. Mike Braun [R-IN] |
History
| Date | Chamber | Action |
|---|---|---|
| 2023-09-07 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
SB3393 (Related) 2024-02-01 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 319.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/senate-bill/2737/all-info |
| Text | https://www.congress.gov/118/bills/s2737/BILLS-118s2737is.pdf |
